Literature DB >> 7924211

Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use.

K Waites1, K Rand, S Jenkins, B Yangco, E Brookings, D Gaskins, J Lewis, K Halkias.   

Abstract

In vitro activities of ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, and seven other oral antimicrobials including amoxicillin-clavulanic acid (A/C), oxacillin, cefaclor, cefixime, cefuroxime, erythromycin, and trimethoprim-sulfamethoxazole (T/S) were evaluated against 1708 fresh bacterial isolates from four hospital laboratories approximately 4 years after the introduction of ciprofloxacin. T/S and ofloxacin had the lowest MIC90s and greatest percentage of susceptible strains overall, followed by the other three quinolones. Quinolones were the most active drugs tested against Gram-negative bacteria, with little variation in the activity among the four compounds against most species. Quinolone resistance was detected to some degree in the majority of Gram-negative species tested, with Pseudomonas, Acinetobacter, Xanthomonas, and Providencia demonstrating the highest percentage of resistant strains. Ofloxacin and ciprofloxacin were relatively more active against Gram-positive bacteria than were fleroxacin and lomefloxacin, but T/S and A/C had more susceptible strains than any of the quinolones. Oxacillin-resistant staphylococci, enterococci, and streptococci exhibited the least quinolone susceptibility. This study showed that while resistance is developing among several previously susceptible bacterial species, quinolones remain important alternatives for the oral treatment of many types of infections. Actions to prevent or limit resistance will be important to maintain the viability of the quinolones as therapeutic agents in both hospital and community environments.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924211     DOI: 10.1016/0732-8893(94)90089-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Activities of oral antibiotics on Providencia strains isolated from institutionalized elderly patients with urinary tract infections.

Authors:  G Cornaglia; S Frugoni; A Mazzariol; E Piacentini; A Berlusconi; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 2.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

3.  Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.

Authors:  D F Sahm; J A Karlowsky; L J Kelly; I A Critchley; M E Jones; C Thornsberry; Y Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.

Authors:  C D Steward; S A Stocker; J M Swenson; C M O'Hara; J R Edwards; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

6.  In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.

Authors:  M Araque; E Velazco
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 7.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

8.  In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.

Authors:  R K Flamm; C Vojtko; D T Chu; Q Li; J Beyer; D Hensey; N Ramer; J J Clement; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.